Can a new pill tame psoriasis? early safety trial begins
NCT ID NCT07736586
First seen Jul 30, 2026 · Last updated Aug 04, 2026 · Updated 3 times
Summary
This early-stage trial is testing an experimental oral drug called HL40626S in healthy adults aged 18 to 55. The goal is to check the drug's safety, how the body processes it, and the best dose range. If it passes these initial safety checks, the drug could eventually be studied as a treatment for psoriasis, a chronic skin condition caused by an overactive immune system.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- an experimental oral drug called HL40626S
- What this could lead to
- If safe and effective, HL40626S could become a new oral treatment option for psoriasis, an inflammatory skin condition.
- What could go wrong
- This is an early Phase 1 trial in healthy volunteers, not patients. It primarily tests safety and dosing, not whether the drug works for psoriasis. Side effects or lack of efficacy in later trials are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE SYSTEM DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nucleus Network Pty Ltd
Melbourne, 3004, Australia
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a common blood thinner shield psoriasis Patients' arteries?
- Study aims to unlock secrets of immunotherapy skin reactions
- Psoriasis patients: does your injection schedule matter?
- New psoriasis cream takes on old standby in Head-to-Head trial
- World's largest psoriasis care study launches to uncover treatment gaps
- Skin deep: european study probes the hidden emotional toll of skin diseases